Form 4 for ANTX AN2 Therapeutics, Inc.
Accepted 2024-03-18 00:00:00 ET · period of report 2024-03-15 · accession 0001610717-24-000167 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-18 | 2024-03-15 | ANTX | Krause Kevin Michael | Chief Strategy Off | A - Grant | $0.00 | +30.0K | 31.9K | +1,567% | $0 |
| D | 2024-03-18 | 2024-03-15 | ANTX | Krause Kevin Michael | Chief Strategy Off | A - Grant | $0.00 | +60.0K | 60.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-15 | A | A | 30,000 | $0.00 | 31,914 | D | — | — | (F1) These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. |
| 2 | Derivative | Stock Option (right to buy) | 2024-03-15 | A | A | 60,000 | $0.00 | 60,000 | D | $3.00 · — to 2034-03-14 | 60,000 Common Stock | (F2) The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. |